C2CD2L

Across TCGA pan-cancer cohorts, C2CD2L mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated C2CD2L data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher C2CD2L mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated C2CD2L expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where C2CD2L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	1.000	0.800	.003	23	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	11	view →
PDAC	DFS	Quartile	III,IV	0.774	0.196	.024	6	view →
GBM	OS	Quartile	All	0.314	0.682	.023	5	view →
HNSC	OS	Median	All	0.795	0.622	.031	4	view →
LSCC	DFS	Tertile	All	0.761	0.344	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

C2CD2L–CCRCC (DFS)

Open the CCRCC breakdown →